News | February 20, 2022
GSK pauses phase III RSV maternal vaccine candidate programme
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
The entire integration and transition of the brands is expected to be completed by March 2022
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
The vagus nerve is the longest nerve in the body that travels down from the brain to innervate and control breathing, stress levels and inflammation
Cysoni is a bionic device that paces the heart with real-time respiratory modulation. The innovation stems from the idea that heart rate increases and decreases with each breath in normal physiology, termed ‘respiratory sinus arrhythmia’ (RSA)
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
Subscribe To Our Newsletter & Stay Updated
